U.S. Uterine Fibroid Treatment Market Size and Trends

U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, and MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Laparoscopic Hysterectomy, Robotic Hysterectomy, and Hysteroscopic Morcellation), Myomectomy (Open Myomectomy, Laparoscopic Myomectomy, and Robotic Myomectomy), Uterine Artery Embolization, Radiofrequency Ablation, and Others) and By End User (Hospitals and Ambulatory Surgical Centers)-

Published In : Jun 2023

Code : CMI3866

Pages :166

Formats :

Excel and PDF

Industry : Medical Devices

U.S. Uterine Fibroid Treatment MarketSize and Trends

U.S uterine fibroids treatment market is estimated to be valued at US$ 269.4 million in 2023 and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Over the forecast period, the U.S. uterine fibroids treatment market is anticipated to rise because of the high prevalence of uterine fibroids among women, the adoption of minimally invasive therapies, and robotic procedures. For instance, in February 2021, according to the Office of the Assistant Secretary for Health (OASH) at the U.S. Department of Health and Human Services, about 20-80 % of women develop fibroids by the time they reach age 50, and fibroids become more common as women age, especially during the 30s and 40s through menopause.

Figure 1. U.S Uterine Fibroids Treatment Market Share (%), By Procedure, 2023

U.S Uterine Fibroids Treatment Market–Drivers

High incidence of uterine fibroids among women

Increasing incidence of uterine fibroids among women is expected to boost growth of the U.S uterine fibroids treatment market over the forecast period. For instance, on May 13 2023, according to an article published in the Journal of Biomed Central Women's Health, the prevalence of UL (Uterine leiomyomata (Fibroids)) was approximately 12.92% in U.S. in 2020, and is estimated to increase up to 80 % by 2025.

Rising number of hysterectomy

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the hysterectomy will likely grow as the number of related surgeries increases. For instance, in November 2020, according to an article published in the Journal of Gynecologic Oncology, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United State each year. For instance in November 2022, according to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

Figure 2. U.S. Uterine Fibroids Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2030

U.S Uterine Fibroids Treatment Market: Key Trends

Investigating novel hormonal medical therapy

Increasing need to treat heavy menstrual bleeding and surging demand of novel hormonal medical therapy, the U.S uterine fibroids treatment market is expected to experience considerable expansion over the forecast period. For instance, in March 2022, according to an article published in the Journal of Yangtze Medicine, Ulipristal acetate (UPA) has been the first selective progesterone-receptor modulator (SPRM) approved for the pre-operative and long-term management of uterine fibroids. The use of ulipristal acetate is supported by research suggesting that progesterone pathways play a significant role in the pathogenesis of uterine fibroids. Alternatives to surgical intervention must be available, especially for people who want to maintain their fertility and uterus. Ulipristal acetate is one of the alternatives that has been shown to be useful in treating fibroid symptoms.